Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway

Journal of Thoracic Oncology

Volumn 3, Issue 2, 2008, Pages 170-173

  Sos, Martin L ^a,b   Zander, Thomas ^a   Thomas, Roman K ^a,b   Staratschek Jox, Andrea ^a   Claasen, Julia ^a   Wolf, Jürgen ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

AKT; EGFR; Gefitinib; KRAS; PTEN; SH 6

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SH 6; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 40049089468     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181622c05     Document Type: Article

References (16)

1. TJ Lynch DW Bell R Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
2. S Kobayashi TJ Boggon T Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
3. W Pao VA Miller KA Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
4. BR Balsara J Pei Y Mitsuuchi Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis 25 2004 2053 2059
5. S Rodenhuis RJ Slebos AJ Boot Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung Cancer Res 48 1988 5738 5741
6. DA Guertin DM Sabatini An expanding role for mTOR in cancer Trends Mol Med 11 2005 353 361
7. RK Thomas ML Sos T Zander Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies Clin Cancer Res 11 2005 8186 8194
8. JG Paez PA Janne JC Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
9. W Pao V Miller M Zakowski KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
10. SV Sharma DW Bell J Settleman DA Haber Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
11. S Kobayashi H Ji Y Yuza An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor Cancer Res 65 2005 7096 7101
12. DW Fry AJ Bridges WA Denny Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor Proc Natl Acad Sci USA 95 1998 12022 12027
13. EL Kwak R Sordella DW Bell Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci USA 102 2005 7665 7670
14. T Shimamura AM Lowell JA Engelman GI Shapiro Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized after exposure to geldanamycins Cancer Res 65 2005 6401 6408
15. SS Castillo J Brognard PA Petukhov Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues Cancer Res 64 2004 2782 2792
16. WC Noh WH Mondesire J Peng Determinants of rapamycin sensitivity in breast cancer cells Clin Cancer Res 10 2004 1013 1023